When generics turn into Big Pharma
Top generics firms, some from India, are charged with price-fixing and sleazy deals; Sun Pharma has paid up to settle claims
COVID-19 also brings focus back on pollution due to pharmaceuticals
No time for quick-fix measures. India needs stricter laws
COVID-19 underlines medicine interdependency, which is not good: Experts
Countries must come out of global value chain and become self-dependent, they said
Look back at the decade: Generic drugs
Fifteen years after it rose and went limp, the biotech sector saw a bull run of sorts
Pills by jugaad: Excerpts from Bottle of Lies
A new investigative book, Bottle of Lies, says that Indian cancer drugs are contaminated; cholesterol medication has shards of glass; and, blood …
Six reasons why antibiotics access remains a challenge in Uganda
Lack of registry, sub-standard health facilities, poor cold storage, limited expenditure on health, irrational antibiotic use and lack of …
Colour code for generic medicines a no-brainer
There are a number of systemic gaps without addressing which the government’s latest plan for the pharma sector won’t work
Beware of Japan's trade ambitions
Japan is pushing for higher levels of intellectual property protection that will cut access to affordable medicines
This is why Hepatitis B, Hepatitis C are dangerous
Just one in 10 infected know their status and many are unaware that the inflamation of the liver is a common and treatable disease
Civil society challenges patents on Hepatitis C drugs
Pharmaceutical corporations obtain unjustified patents making the drugs unaffordable to many, petitioners claim
Highlights of 2016 International AIDS Conference in South Africa
South Africa has the highest infection rate in the world with about seven million affected
Gilead signs agreements with Indian generic companies for hepatitis C drug
Indian companies granted licence to produce generic sofosbuvir and investigational single tablet regimen of ledipasvir/sofosbuvir for treatment …
US keeps India out of Priority Foreign Country list of 'worst IP offenders'
US Trade Representative’s Special 301 Report keeps up pressure on India to fall in line with US’ interests
Novartis loses patent appeal in landmark suit
Supreme Court upholds amended law that bars patents for insignificant improvements to an existing drug—in this case anti-cancer drug …
Government stand against EU ban on Indian drugs much needed, says industry
Standing against the arbitrary ban on 700 drugs, India has decided to defer the proposed talks on the free trade agreement between India and the EU
Generic drugs needed to eliminate Hepatitis C, say experts
Currently, medicines available to treat patients are exorbitantly priced
Ranbaxy effect: Indian government defends pharma industry
Few isolated cases cannot undermine well regulated system, says commerce ministry
Profits and not improving accessibility matter to Indian drug makers
FICCI conference organised to discuss access to generic medicines focuses more on increasing exports
AAP promises to improve health set-up and promote generic medicines in Delhi
Party says it will address health concerns of both the elderly and the young if it is voted to power
Activists demand compulsory licence for another life-saving cancer drug
Appellate board's order upholding Natco's CL for sorafenib tosylate may pave way for manufacture of generic version of other patented drugs
EU fines nine pharma companies for violating competition rules
Lundbeck pharma made other companies enter market late with generic versions of its drug citalopram
Vidarbha gets its first generic medicines shop
Challenge to popularising these stores is to get doctors to prescribe low-cost generic drugs
European Parliament rejects Anti-Counterfeiting Trade Agreement
Act makes it possible to seize and destroy even legitimately produced generic drugs exported from India to poor countries
Substantiate allegations against Ranbaxy, says Supreme Court
Experts say allegations against the generic pharma company motivated by vested interests
‘PESTICIDES’ IN DRUGS
Sharad Pawar’s provision for protecting test data in the Pesticides Bill could spill over into trade agreements and hit the drugs industry, too